(Q36225322)

12 August 2017

Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics (English)

1 reference

alpha-1-antitrypsin deficiency

12 August 2017

1 reference

1 reference

D Soy

1

1 reference

12 August 2017

C de la Roza

2

1 reference

12 August 2017

B Lara

3

1 reference

12 August 2017

C Esquinas

4

1 reference

12 August 2017

A Torres

5

1 reference

12 August 2017

M Miravitlles

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

23 August 2006

1 reference

12 August 2017

1 reference

12 August 2017

61

1 reference

12 August 2017

12

1 reference

12 August 2017

1059-1064

1 reference

Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Some suggestions for measuring predictive performance

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Alpha1-antitrypsin deficiency: situation in Spain and development of a screening program

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

The randomized placebo-phase design for clinical trials.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

The direct medical costs of alpha(1)-antitrypsin deficiency.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency--three-year follow-up.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117047

Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events

22 September 2018

1 reference

12 December 2020

Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency

1 reference

12 December 2020

Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin

1 reference

12 December 2020

Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients

1 reference

12 December 2020

Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency

1 reference

12 December 2020

Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency

1 reference

12 December 2020

Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group

1 reference

12 December 2020

The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency

1 reference

12 December 2020

Identifiers

DOI

10.1136/THX.2005.057943

1 reference

12 August 2017

1 reference

12 August 2017

1 reference